Inadequate molecular and clinical stratification of the patients with high-risk diffuse large B-
cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized …

Accessible and real-time genotyping for diagnostic, prognostic, or treatment purposes is
increasingly impelling in diffuse large B-cell lymphoma (DLBCL). Cell-free DNA (cfDNA) is …

From a liquid biopsy, cell-free DNA (cfDNA) can provide information regarding basal tumoral
genetic patterns and changes upon treatment. In a prospective cohort of 30 diffuse large B …

Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor
behavior and outcomes, yet the identification of poor-risk groups remains challenging. In …

Purpose: We analyzed the utility of cell-free DNA (cfDNA) in a prospective population-based
cohort to determine the mutational profile, assess tumor burden, and estimate its impact in …

Lack of remission or early relapse remains a major clinical issue in diffuse large B-cell
lymphoma (DLBCL), with 30% of patients failing standard of care. Although clinical factors …

Molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) underlies the variable
outcomes achieved with immunochemotherapy. However, outcomes of gene expression …

In this article, we broadly review the application of cfDNA analysis to the diagnosis and
management of lymphoma. We introduce the advantages of cfDNA measurement over …

The most frequent mature aggressive B-cell lymphomas are diffuse large B-cell lymphoma
(DLBCL) and Burkitt lymphoma (BL). Patients suffering from molecularly defined BL (mBL) …

Purpose Outcomes for patients with diffuse large B-cell lymphoma remain heterogeneous,
with existing methods failing to consistently predict treatment failure. We examined the …